RT Article
T1 PROFITS AND PLAGIARISM: THE CASE OF MEDICAL GHOSTWRITING
JF Bioethics
VO 24
IS 6
SP 267
OP 272
A1 Anekwe, Tobenna D.
LA English
YR 2010
UL https://ixtheo.de/Record/1781882452
AB This paper focuses on medical ghostwriting in the United States. I argue that medical ghostwriting often involves plagiarism and, in those cases, can be treated as an act of research misconduct by both the federal government and research institutions. I also propose several anti-ghostwriting measures, including: 1) journals should implement guarantor policies so that researchers may be better held accountable for their work; 2) research institutions and the federal government should explicitly prohibit medical ghostwriting and outline appropriate penalties; and 3) a publicly available database should be created to record researchers' ethics violations.
K1 research misconduct
K1 Public Health
K1 Plagiarism
K1 pharmaceutical companies
K1 Medical Ethics
K1 honorary authors
K1 ghostwriting
DO 10.1111/j.1467-8519.2008.00705.x